CEBPA and hepatocellular carcinoma: As immunosuppressive myeloid cells are the most likely cause of TKI resistance in HCC models [67,68], prior treatment with MTL-CEBPA is thought to reverse this suppression to allow for better efficacy of the TKI treatment.